State medical institute snares $30M grant from feds

Back to TopCommentsE-mailPrintBookmark and Share

A statewide medical initiative involving some of Indiana’s biggest universities has received nearly $30 million to continue its work taking laboratory and clinical discoveries and translating them into treatments for patients.

The National Institutes of Health awarded the grant to the Indiana Clinical and Translational Sciences Institute, a partnership among Indiana University, Purdue University and University of Notre Dame. The money will help fund the institute at least through 2018.

"I regard this award as a powerful vote of confidence in the Indiana CTSI's success over the past five years, as well as a promise on our part to achieve even greater heights going into the next phase of this project,” said Dr. Anantha Shekar, director of ICTSI.

The Indiana University School of Medicine established the Institute in 2008 with a $25 million NIH grant, plus about $25 million in matching grants from IU, Purdue, the state of Indiana and public-private partners such as Eli Lilly and Co.

Since 2008, ICTSI-funded researchers at the three partner universities have advanced discoveries in areas such as Alzheimer's disease, Parkinson's disease, autism, traumatic brain injury, polycystic kidney disease, and osteoporosis and osteoarthritis.

In addition, ICTSI estimates it supports more than 80 full-time equivalent professional jobs across Indiana.

"In 2009 alone, Indiana CTSI invested $1.1 million in scientists whose work later attracted more than $30 million in outside investment," Dr. Shekhar said. "These numbers show that our institute has become a powerful magnet to attract innovation and research dollars to Indiana.

“Our focus on partnerships with groups such as Eli Lilly and Co., Roche Diagnostics and Cook Medical Group—as well as the patents, licenses and spinoffs we've fostered—illustrate we're also playing a vital role fueling the state's economy."


Post a comment to this story

We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
You are legally responsible for what you post and your anonymity is not guaranteed.
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
Subscribe to IBJ